R&D On the ICH E20 draft guideline (2025) for adaptive clinical ... A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.
News Novo Nordisk microRNA drug fluffs its lines in heart failure A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.
News Bayer plans filings for cardiac amyloidosis imaging agent Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.
News CellCentric pockets $220m for blood cancer programme CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
Market Access Anglonordic Life Science 2026: A focus on execution The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
News After rival fails, Cytokinetics could broaden Myqorzo label Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
